jman,
Welcome! IMO FLML is a sleeping giant, with few followers here in the states.
What FLML has going for them is unique....they are forming alliance deals in which they have no increased development expense and will merely pull in royalty payment. For example is the latest deal...
"Flamel Technologies (FLML: news, chart, profile) rose more than 8 percent after the company agreed to license its Micropump technology -- a controlled release technology for the oral administration of small molecule drugs -- to GlaxoSmithKline (GSK: news, chart, profile), which intends to use the technology to develop a new formulation for an undisclosed product. The deal could lead to payments of up to $45 million to Flamel by the end of the first year of launch of the product. As part of the deal, Flamel will receive an upfront payment of $2 million, additional milestone payments based on the achievement of certain events and royalties on sales of the product>"
Pulling in a potential of $45 million is huge...and considering this amount will be brought directly to the bottomline we are looking at a huge net income for this stock. And this deal is only for this second announcement, leaving IMO the deal signed last year for Augmentin to even generate more than this latest deal.
Glaxo had to know and had to like what they have seen with FLML's technology for them to come right back and sign this second deal....
Good luck to you ...and good luck for FLML! |
